Growth Metrics

Collegium Pharmaceutical (COLL) Equity Average (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Equity Average data on record, last reported at $253.5 million in Q3 2025.

  • For Q3 2025, Equity Average rose 12.45% year-over-year to $253.5 million; the TTM value through Sep 2025 reached $253.5 million, up 12.45%, while the annual FY2024 figure was $212.1 million, 8.71% up from the prior year.
  • Equity Average reached $253.5 million in Q3 2025 per COLL's latest filing, up from $233.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $253.5 million in Q3 2025 and bottomed at $178.0 million in Q1 2021.
  • Average Equity Average over 5 years is $211.4 million, with a median of $208.8 million recorded in 2024.
  • Peak YoY movement for Equity Average: skyrocketed 55.83% in 2021, then fell 21.69% in 2022.
  • A 5-year view of Equity Average shows it stood at $227.0 million in 2021, then fell by 13.65% to $196.0 million in 2022, then decreased by 4.52% to $187.2 million in 2023, then grew by 23.73% to $231.6 million in 2024, then grew by 9.48% to $253.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $253.5 million in Q3 2025, $233.3 million in Q2 2025, and $231.6 million in Q1 2025.